Iterum Therapeutics plc - Ordinary Share (ITRM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ITRM Stock Price Chart Interactive Chart >
ITRM Price/Volume Stats
|Current price||$0.21||52-week high||$1.63|
|Prev. close||$0.20||52-week low||$0.18|
|Day high||$0.23||Avg. volume||1,357,304|
|50-day MA||$0.23||Dividend yield||N/A|
|200-day MA||$0.39||Market Cap||39.13M|
Iterum Therapeutics plc - Ordinary Share (ITRM) Company Bio
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is based in Dublin, Ireland.
Most Popular Stories View All
ITRM Latest News Stream
|Loading, please wait...|
ITRM Latest Social Stream
View Full ITRM Social Stream
Latest ITRM News From Around the Web
Below are the latest news stories about Iterum Therapeutics plc that investors may wish to consider to help them evaluate ITRM as an investment opportunity.
We've got another busy week of trading ahead of us so let's start it off with the biggest pre-market stock movers for Monday!
The trading price of Iterum Therapeutics plc (NASDAQ:ITRM) closed lower on Monday, December 13, closing at $0.47, -1.88% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
DUBLIN, Ireland and CHICAGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has granted a non-statutory share option to purchase an aggregate of 1,800,000 ordinary shares of Iterum Therapeutics and 500,000 restricted share units to Sailija Puttagunta, M.D., Iterum Therapeutics newly appointed Chief Medical Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical developme
ITRM Price Returns
Continue Researching ITRMWant to see what other sources are saying about Iterum Therapeutics plc's financials and stock price? Try the links below:
Iterum Therapeutics plc (ITRM) Stock Price | Nasdaq
Iterum Therapeutics plc (ITRM) Stock Quote, History and News - Yahoo Finance
Iterum Therapeutics plc (ITRM) Stock Price and Basic Information | MarketWatch